Merck Reports Positive Clinical Trial Results for Kidney Cancer Therapies
Key Facts
- •The combination of KEYTRUDA and WELIREG reduced the risk of disease recurrence or death by 28% in patients with earlier-stage renal cell carcinoma (RCC).
- •WELIREG plus LENVIMA reduced the risk of disease progression or death by 30% compared to cabozantinib in certain previously treated patients with advanced RCC.
Merck (MRK) announced significant positive results from two clinical trials evaluating combination therapies for renal cell carcinoma (RCC). In the LITESPARK-022 trial, the combination of KEYTRUDA and WELIREG reduced the risk of disease recurrence or death by 28% in patients with early-stage RCC. Additionally, the LITESPARK-011 study showed that WELIREG plus LENVIMA reduced the risk of disease progression or death by 30% compared to cabozantinib in advanced cases. These results aim to establish new standards of care and expand the indications for Merck's oncology portfolio. The data reinforces the long-term revenue potential for blockbuster drugs like KEYTRUDA. Investors view these clinical advancements as a positive driver for the company's valuation in the healthcare sector.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis